Cargando…
Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors
The incidence of liver metastasis in digestive neuroendocrine tumors is high. Their presence appears as an important prognostic factor in terms of quality of life and survival. These tumors may be symptomatic because of the tumor burden itself and/or the hormonal hyper-secretion induced by the tumor...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912565/ https://www.ncbi.nlm.nih.gov/pubmed/31703375 http://dx.doi.org/10.3390/jcm8111907 |
_version_ | 1783479486702944256 |
---|---|
author | Dermine, Solène Palmieri, Lola-Jade Lavolé, Julie Barré, Amélie Dohan, Antony Abou Ali, Einas Cottereau, Anne-Ségolène Gaujoux, Sébastien Brezault, Catherine Chaussade, Stanislas Coriat, Romain |
author_facet | Dermine, Solène Palmieri, Lola-Jade Lavolé, Julie Barré, Amélie Dohan, Antony Abou Ali, Einas Cottereau, Anne-Ségolène Gaujoux, Sébastien Brezault, Catherine Chaussade, Stanislas Coriat, Romain |
author_sort | Dermine, Solène |
collection | PubMed |
description | The incidence of liver metastasis in digestive neuroendocrine tumors is high. Their presence appears as an important prognostic factor in terms of quality of life and survival. These tumors may be symptomatic because of the tumor burden itself and/or the hormonal hyper-secretion induced by the tumor. Surgery is the treatment of choice for resectable tumors and metastasis. Nevertheless, surgery is only possible in a small number of cases. The management of non-resectable liver metastasis is a challenge. The literature is rich but consists predominantly in small retrospective series with a low level of proof. Thus, the choice of one technique over another could be difficult. Local ablative techniques (radiofrequency) or trans-catheter intra-arterial liver-directed treatments (hepatic artery embolization, chemo-embolization, and radio-embolization) are frequently considered for liver metastasis. In the present review, we focus on these different therapeutic approaches in advanced neuroendocrine tumors, results (clinical and radiological), and overall efficacy, and summarize recommendations to help physicians in their clinical practice. |
format | Online Article Text |
id | pubmed-6912565 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69125652020-01-02 Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors Dermine, Solène Palmieri, Lola-Jade Lavolé, Julie Barré, Amélie Dohan, Antony Abou Ali, Einas Cottereau, Anne-Ségolène Gaujoux, Sébastien Brezault, Catherine Chaussade, Stanislas Coriat, Romain J Clin Med Review The incidence of liver metastasis in digestive neuroendocrine tumors is high. Their presence appears as an important prognostic factor in terms of quality of life and survival. These tumors may be symptomatic because of the tumor burden itself and/or the hormonal hyper-secretion induced by the tumor. Surgery is the treatment of choice for resectable tumors and metastasis. Nevertheless, surgery is only possible in a small number of cases. The management of non-resectable liver metastasis is a challenge. The literature is rich but consists predominantly in small retrospective series with a low level of proof. Thus, the choice of one technique over another could be difficult. Local ablative techniques (radiofrequency) or trans-catheter intra-arterial liver-directed treatments (hepatic artery embolization, chemo-embolization, and radio-embolization) are frequently considered for liver metastasis. In the present review, we focus on these different therapeutic approaches in advanced neuroendocrine tumors, results (clinical and radiological), and overall efficacy, and summarize recommendations to help physicians in their clinical practice. MDPI 2019-11-07 /pmc/articles/PMC6912565/ /pubmed/31703375 http://dx.doi.org/10.3390/jcm8111907 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Dermine, Solène Palmieri, Lola-Jade Lavolé, Julie Barré, Amélie Dohan, Antony Abou Ali, Einas Cottereau, Anne-Ségolène Gaujoux, Sébastien Brezault, Catherine Chaussade, Stanislas Coriat, Romain Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors |
title | Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors |
title_full | Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors |
title_fullStr | Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors |
title_full_unstemmed | Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors |
title_short | Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors |
title_sort | non-pharmacological therapeutic options for liver metastases in advanced neuroendocrine tumors |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912565/ https://www.ncbi.nlm.nih.gov/pubmed/31703375 http://dx.doi.org/10.3390/jcm8111907 |
work_keys_str_mv | AT derminesolene nonpharmacologicaltherapeuticoptionsforlivermetastasesinadvancedneuroendocrinetumors AT palmierilolajade nonpharmacologicaltherapeuticoptionsforlivermetastasesinadvancedneuroendocrinetumors AT lavolejulie nonpharmacologicaltherapeuticoptionsforlivermetastasesinadvancedneuroendocrinetumors AT barreamelie nonpharmacologicaltherapeuticoptionsforlivermetastasesinadvancedneuroendocrinetumors AT dohanantony nonpharmacologicaltherapeuticoptionsforlivermetastasesinadvancedneuroendocrinetumors AT aboualieinas nonpharmacologicaltherapeuticoptionsforlivermetastasesinadvancedneuroendocrinetumors AT cottereauannesegolene nonpharmacologicaltherapeuticoptionsforlivermetastasesinadvancedneuroendocrinetumors AT gaujouxsebastien nonpharmacologicaltherapeuticoptionsforlivermetastasesinadvancedneuroendocrinetumors AT brezaultcatherine nonpharmacologicaltherapeuticoptionsforlivermetastasesinadvancedneuroendocrinetumors AT chaussadestanislas nonpharmacologicaltherapeuticoptionsforlivermetastasesinadvancedneuroendocrinetumors AT coriatromain nonpharmacologicaltherapeuticoptionsforlivermetastasesinadvancedneuroendocrinetumors |